No influence of DTNBP1 polymorphisms on the response to aripiprazole.
OBJECTIVE
The aim of the present study was to investigate possible influences of a panel of markers in the dysbindin gene DTNBP1 (rs3213207, rs1011313, rs2005976, rs760761 and rs2619522) on the clinical outcome and side effects associated to the treatment with aripiprazole in schizophrenic patients.


METHODS
Efficacy was assessed at baseline and weeks 1, 2, 4, 6 and 8 using the Clinical Global Impression Severity and Improvement Scales, the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms. Side effects were evaluated by the Simpson-Angus, Barnes Akathisia and Abnormal Involuntary Movement Scales. Multivariate analysis of covariance was used to test possible influences of single nucleotide polymorphisms on clinical and safety scores. Analysis of haplotypes was also performed.


RESULTS
No relevant association between DTNBP1 variants and clinical or safety scores was observed. Additionally, haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well.


CONCLUSIONS
Our data suggest no association between the investigated alleles and genotypes in DTNBP1 and the response to aripiprazole. However, because several limitations characterize the present study, further investigations are required.
Pae
Chi-Un
CU
Department of Psychiatry, Bucheon St. Mary's Hospital, Catholic University of Korea College of Medicine, Bucheon, Republic of Korea. pae@catholic.ac.kr
Chiesa
Alberto
A
Mandelli
Laura
L
Serretti
Alessandro
A
D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D002352:Carrier Proteins / Q000235:genetics*; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D005260:Female; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D014150:Antipsychotic Agents; D002352:Carrier Proteins; C432416:DTNBP1 protein, human; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole